Home  |  Contact
Due to maintenance work, this service will be unavailable Mon Feb 13 between 07:00 and 09:30 - CET. Apologies for the inconvenience.

Cellosaurus SUM52PE (CVCL_3425)

[Text version]

Cell line name SUM52PE
Synonyms SUM-52PE; SUM 52PE; SUM-52-PE; SUM-52; SUM 52; SUM52; 52PE
Accession CVCL_3425
Resource Identification Initiative To cite this cell line use: SUM52PE (RRID:CVCL_3425)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: GrayJW breast cancer cell line panel.
Doubling time: 55.21 hours (GrayJW panel).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: miRNA expression profiling.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations
  • Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68Val (c.203C>T); ClinVar=VCV000406701; Zygosity=Homozygous (PubMed=19593635; DepMap).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=16541312; DepMap).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*32:01,32:01
HLA-BB*07:02,15:01
HLA-CC*03:03,07:02
Class II
HLA-DQDQB1*06:04,05:01
HLA-DRDRB1*15:01,15:01
Disease Breast carcinoma (NCIt: C4872)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_A1FM (SUM52PE GDC-0941_resistant)
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): DepMap; PubMed=25877200

Markers:
AmelogeninX
CSF1PO10,11
D3S135818
D5S81811,12
D7S82012,14 (DepMap)
14 (PubMed=25877200)
D8S117913
D13S31712
D16S53910
D18S5116
D21S1127,28
FGA21 (PubMed=25877200)
21,22 (DepMap)
Penta D9,12
Penta E13,17
TH017,9.3
TPOX8
vWA17

Run an STR similarity search on this cell line
Web pages https://www.cellosaurus.org/pawefish/BreastCellLineDescriptions/SUM52.html
http://www.cells-talk.com/index.php/page/copelibrary?key=SUM-52PE
https://bioivt.com/sum-breast-cancer-cell-lines/
https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
Publications

PubMed=10424408; DOI=10.1023/A:1006135331912
Ignatoski K.M.W., Ethier S.P.
Constitutive activation of pp125fak in newly isolated human breast cancer cell lines.
Breast Cancer Res. Treat. 54:173-182(1999)

PubMed=10604729; DOI=10.1038/sj.bjc.6695007
Forozan F., Veldman R., Ammerman C.A., Parsa N.Z., Kallioniemi A., Kallioniemi O.-P., Ethier S.P.
Molecular cytogenetic analysis of 11 new breast cancer cell lines.
Br. J. Cancer 81:1328-1334(1999)

PubMed=10969801
Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Cancer Res. 60:4519-4525(2000)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=16541312; DOI=10.1007/s10549-006-9186-z
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res. Treat. 99:97-101(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=19582160; DOI=10.1371/journal.pone.0006146
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)

PubMed=19593635; DOI=10.1007/s10549-009-0460-8
Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Cancer Res. Treat. 121:53-64(2010)

PubMed=21778573; DOI=10.3233/BD-2010-0307
Chavez K.J., Garimella S.V., Lipkowitz S.
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Breast Dis. 32:35-48(2010)

PubMed=23401782; DOI=10.1155/2013/872743
Barnabas N., Cohen D.
Phenotypic and molecular characterization of MCF10DCIS and SUM breast cancer cell lines.
Int. J. Breast Cancer 2013:872743.1-872743.16(2013)

PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33.1-R33.17(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26759240; DOI=10.1158/0008-5472.CAN-15-2201
Nakanishi Y., Walter K., Spoerke J.M., O'Brien C., Huw L.Y., Hampton G.M., Lackner M.R.
Activating mutations in PIK3CB confer resistance to PI3K inhibition and define a novel oncogenic role for p110beta.
Cancer Res. 76:1193-1203(2016)

PubMed=32715085; DOI=10.1038/s41523-020-0173-z
Ethier S.P., Guest S.T., Garrett-Mayer E., Armeson K., Wilson R.C., Duchinski K., Couch D., Gray J.W., Kappler C.
Development and implementation of the SUM breast cancer cell line functional genomics knowledge base.
NPJ Breast Cancer 6:30.1-30.14(2020)

Cross-references
Cell line databases/resources Cell_Model_Passport; SIDM01422
DepMap; ACH-001396
LINCS_HMS; 51087
LINCS_LDP; LCL-2071
Lonza; 1253
SLKBase; 231
Anatomy/cell type resources BTO; BTO:0005390
Biological sample resources BioSample; SAMN03472911
Chemistry resources PharmacoDB; SUM52PE_1513_2019
Encyclopedic resources Wikidata; Q54970851
Experimental variables resources EFO; EFO_0001246
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-TABM-157
GEO; GSM115109
GEO; GSM217604
GEO; GSM219890
GEO; GSM320178
GEO; GSM350524
GEO; GSM421887
GEO; GSM481330
GEO; GSM847439
GEO; GSM847506
GEO; GSM844711
GEO; GSM844712
GEO; GSM1053739
GEO; GSM1172903
GEO; GSM1172998
GEO; GSM1374912
Polymorphism and mutation databases Cosmic; 904387
Cosmic; 1046962
Cosmic; 1176647
Cosmic; 1287897
Cosmic; 1289409
Cosmic; 1460238
IARC_TP53; 24366
Progenetix; CVCL_3425
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001002554
Entry history
Entry creation04-Apr-2012
Last entry update15-Dec-2022
Version number34